May 23, 2022Annals of the Rheumatic DiseasesOpen Access

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

View Full Paper

Ask AI

Bookmark

Abstract

These points-to-consider are evidence-based and consensus-based statements for the use of TDM of biopharmaceuticals in inflammatory RMDs, addressing the clinical utility of TDM.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Krieckaert et al. (2022) studied this question.

synapsesocial.com/papers/69d8f9692c39562886ae3918 https://doi.org/10.1136/annrheumdis-2022-222155

View Full Paper

Ask AI

Bookmark

Abstract

These points-to-consider are evidence-based and consensus-based statements for the use of TDM of biopharmaceuticals in inflammatory RMDs, addressing the clinical utility of TDM.